GamaMabs Pharma is a private preclinical stage biopharma company, focused on the development of optimized anti-cancer monoclonal antibodies.
GamaMabs Pharma was formed and financed by LFB S.A and Bpifrance and obtained the global development and marketing rights of 3C23K from LFB group.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
GamaMabs Pharma has rights on a glyco-engineering technology (EMABlingë) developed at LFB (France), which enhances the efficacy of mAbs through the activation of immune cells.
In Oct 2017, GamaMabs acquired an exclusive right to utilize MedImmunes proprietary PBD technology to develop an ADC against a single target, suitable as a therapeutic for a broad variety of solid tumors. Under the terms, MedImmune will receive an upfront payment, development and commercial milestone payments, as well as royalties on net sales. MedImmune has the first right to negotiate a license to develop and commercialize products created by GamaMabs with the PBD technology.
In Dec 2015, GamaMabs raised 15 Mn in Series B financing round led by a new investor, BioDiscovery 4, a fund managed by Edmond de Rothschild Investment Partners (EdRIP). All existing GamaMabs investors (InnoBio, Irdinov, Alto Invest, iXO Private Equity) also subscribed to the round. The company raised 3.6 Mn in 2013 in a series A funding round led by InnoBio (Bpifrance).
Recover your password.
A password will be e-mailed to you.